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Abstract Following exposure to 9-(2-phosphonylmethoxy-
ethyl)adenine (an inhibitor of the cellular DNA polymerases
K, N and O), human erythroleukemia K562, human T-lymphoid
CEM and murine leukemia L1210 cells markedly accumulated in
the S phase of the cell cycle. In contrast to DNA replication,
RNA synthesis (transcription) and protein synthesis (mRNA
translation) were not affected by 9-(2-phosphonylmethoxyethyl)-
adenine. The ribonucleoside triphosphate pools were slightly
elevated, while the intracellular levels of all four deoxyribonu-
cleoside triphosphates were 1.5^4-fold increased in 9-(2-phos-
phonylmethoxyethyl)adenine-treated K562, CEM and L1210
cells. The effect of 9-(2-phosphonylmethoxyethyl)adenine on de
novo (thymidylate synthase-mediated) and salvage (thymidine
kinase-mediated) dTTP synthesis was investigated using radio-
labelled nucleoside precursors. The amount of thymidylate
synthase-derived dTTP in the acid soluble pool was 2^4-fold
higher in PMEA-treated than in untreated K562 cells, which is in
accord with the 3^4-fold expansion of the global dTTP level in
the presence of 9-(2-phosphonylmethoxyethyl)adenine. Strik-
ingly, 2-derived dTTP accumulated to a much higher extent (i.e.
16^40-fold) in the soluble dTTP pool upon 9-(2-phosphonyl-
methoxyethyl)adenine treatment. In keeping with this finding, a
markedly increased thymidine kinase activity could be demon-
strated in extracts of 9-(2-phosphonylmethoxyethyl)adenine-
treated K562 cell cultures. Also, in the presence of 200 WM 9-
(2-phosphonylmethoxyethyl)adenine, 14-fold less thymidylate
synthase-derived but only 3-fold less thymidine kinase-derived
dTTP was incorporated into the DNA of the K562 cells. These
data show that thymidine incorporation may be inappropriate as a
cell proliferation marker in the presence of DNA synthesis
inhibitors such as 9-(2-phosphonylmethoxyethyl)adenine. Our
findings indicate that 9-(2-phosphonylmethoxyethyl)adenine
causes a peculiar pattern of (deoxy)ribonucleotide metabolism
deregulation in drug-treated tumor cells, as a result of the
metabolic block imposed by the drug on the S phase of the cell cycle.
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1. Introduction
9-(2-Phosphonylmethoxyethyl)adenine (PMEA) (Fig. 1) is
the prototype congener of the class of acyclic nucleoside phos-
phonates [1]. The oral lipophilic ester prodrug of PMEA,
bis(pivaloyloxymethyl)-PMEA, is currently being explored in
advanced clinical trials for its e⁄cacy against human immu-
node¢ciency virus (HIV) and human hepatitis B virus (HBV)
infections [2]. Not PMEA itself, but its diphosphorylated in-
tracellular metabolite, PMEApp, is responsible for the anti-
viral activity of the drug [3]. Both adenylate kinase [4,5] and
5-phosphoribosyl-1-pyrophosphate synthetase ([3,6], and our
unpublished data) have been suggested to play a role in the
intracellular activation (phosphorylation) of PMEA. Based on
its structural analogy with the natural DNA precursor dATP,
PMEApp competitively inhibits viral DNA polymerases and
reverse transcriptase. When incorporated into the nascent
DNA strand, PMEApp inevitably causes DNA chain termi-
nation because of the lack of a hydroxyl group for further
DNA chain elongation. At higher concentrations, PMEApp
also interferes with the cellular replicative DNA polymerases
K, N and O [7,8]. This results in a marked cytostatic activity of
PMEA against a variety of tumor cell lines.
We have recently shown that PMEA strongly induces dif-
ferentiation in several in vitro tumor cell models, including
human erythroleukemia K562 cells and rat choriocarcinoma
RCHO cells [9^11]. Moreover, PMEA e¡ectively inhibits rat
choriocarcinoma tumor growth in an in vivo model [12],
pointing to the antitumor potential of PMEA and of related
acyclic nucleoside phosphonate analogues. Induction of tumor
cell di¡erentiation by antimetabolites of purine and pyrimi-
dine nucleotide metabolism, such as the IMP dehydrogenase
inhibitor tiazofurin, the dihydrofolate reductase inhibitor
methotrexate and the classical DNA synthesis inhibitors 1-L-
D-arabinofuranosylcytosine (ara-C) and aphidicolin, is a well
documented phenomenon [13]. The ultimate inhibition of cel-
lular DNA replication, common to all these drugs, is assumed
to be the primary trigger for the onset of the di¡erentiation
program in drug-exposed tumor cells [13]. In addition, it can-
not be excluded that (deoxy)ribonucleotide pool imbalances,
caused by these agents, also play a role in antimetabolite-
induced tumor cell di¡erentiation. PMEA, as a direct inhib-
itor of the DNA polymerization process, clearly ¢ts into this
picture.
Although the metabolism of PMEA has been intensively
studied in several cell lines, no detailed investigations have
been performed on the antimetabolic action of the drug.
Therefore, we have now examined the e¡ects of PMEA on
cell cycle distribution, nucleic acid synthesis and de novo and
salvage (deoxy)ribonucleotide metabolism in human erythro-
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leukemia K562, human T-lymphoid CEM and murine leuke-
mia L1210 cells. Our investigations have disclosed novel in-
formation on the (de)regulation of (deoxy)ribonucleotide me-
tabolism in the presence of PMEA and on the biochemical
context in which PMEA, and other agents that directly inhibit
DNA synthesis, may exert its tumor cell di¡erentiation induc-
ing activity.
2. Materials and methods
2.1. Compounds
PMEA was synthesized and generously supplied by Dr. A. Holy
(Czech Academy of Sciences, Prague, Czech Republic) and Dr. N.
Bischofberger (Gilead Sciences, Foster City, CA, USA). Ara-C and
aphidicolin were purchased from Sigma Chemical (St. Louis, MO,
USA).
2.2. Cell culture
Human erythroleukemia K562, human T-lymphoid CEM and mur-
ine leukemia L1210 cells were obtained from the American Type
Culture Collection (Rockville, MD, USA) and were cultured in a
humidi¢ed, CO2-controlled atmosphere in RPMI 1640 medium (Gib-
co, Paisley, UK) supplemented with 10% fetal calf serum (Gibco),
2 mM glutamine and 0.075% NaHCO3 (Flow Laboratories, Irving,
UK). Subcultivations were performed every 3^4 days.
2.3. Flow cytometric cell cycle analysis
Exponentially growing K562, CEM and L1210 cells were exposed
to PMEA at concentrations corresponding to 2^3 and 20^30 times the
respective 50% inhibitory concentration for cell proliferation values
(IC50) of the compound in the di¡erent cell lines (i.e. 24 WM, 70 WM
and 7.5 WM for K562, CEM and L1210 cells, respectively). At 24 h,
the DNA of the cells was stained with propidium iodide using the
CycleTest plus DNA reagent Kit (Becton Dickinson, Le Pont de
Claix, France). The DNA content of the stained K562 cell cultures
was assessed by £ow cytometry on a FACScan equipped with Cell-
Quest software (Becton Dickinson). Cell debris and cell clumps were
excluded from the analysis by conventional dot plot gating.
2.4. Measurement of RNA and protein synthesis via incorporation of
radiolabelled uridine and leucine
Exponentially growing K562, CEM and L1210 cells were seeded in
96-well microtiter plates at a ¢nal density of 1U105 cells/200 Wl well
and PMEA was added at various concentrations (i.e. 0, 1.6, 8, 40, 200
and 1000 WM). After a 24 h incubation at 37‡C, 1 WCi of either
[5-3H]uridine or [4,5-3H]leucine (Moravek Biochemicals, Brea, CA,
USA) was added per microplate well. The cell cultures were then
incubated for another 4 h. Thereafter, the 200 Wl cell suspension
was spotted onto Whatman GF/C glass micro¢ber ¢lter discs
mounted on a Millipore manifold. After washing the ¢lters with
PBS, the acid insoluble cellular material was precipitated on the ¢lters
with ice-cold 10% TCA, washed once with ice-cold 10% TCA, twice
with ice-cold 5% TCA and ¢nally twice with 70% ethanol. The radio-
activity on the ¢lter discs was measured using UltimaGold liquid
scintillation counting £uid (Packard, Meriden, CT, USA).
2.5. Enzymatic determination of intracellular
2P-deoxyribonucleoside-5P-triphosphate pools
Exponentially growing K562, CEM and L1210 cells were harvested
and washed once with RPMI 1640 medium without serum. The cell
pellets were resuspended in ice-cold 0.5 N perchloric acid at 2U106
cells/100 Wl and incubated on ice for 10 min. After centrifugation
(15 000 rpm) at 4‡C for 5 min, the supernatant was neutralized by
addition of an equal volume of tri-n-octylamine/freon-TF solution
(1:4, v/v) and vigorous shaking during 20 min. The cell extracts
were centrifuged at 4‡C for 5 min at 15 000 rpm, whereafter the upper
aqueous phase was carefully collected and stored at 370‡C until fur-
ther analysis. Reaction mixtures for the enzymatic dNTP assays
[14,15] contained 50 mM Tris-HCl pH 8.3, 1 mM 1,4-dithiothreitol,
5 mM MgCl2, 0.25 mg/ml bovine serum albumin, 0.05 A260 units of
alternating copolymer template (i.e. poly(dA-dT).poly(dA-dT) (Phar-
macia Biotech, Uppsala, Sweden) for dATP and dTTP determinations
and poly(dI-dC).poly(dI-dC) (Pharmacia) for dGTP and dCTP deter-
minations), 1.1 WM complementary [3H]dNTP (i.e. [2,8-3H]dATP,
[methyl-3H]dTTP, [8-3H]dGTP and [5-3H]dCTP (Moravek Biochem-
icals) for determinations of dTTP, dATP, dCTP and dGTP, respec-
tively) at a radiospeci¢city of 9.1 Ci/mmol, 10 Wl of dNTP standard
(0^40 pmol) (Pharmacia) or cell extract (undiluted or 1:2 or 1:4 di-
luted) and 0.2 U of Escherichia coli DNA polymerase I Klenow frag-
ment (Pharmacia). The total assay volume was 100 Wl. Reactions were
started by addition of the enzyme and were carried out at 37‡C. After
80 and 100 min, 20 Wl aliquots of the reaction mixtures were spotted
onto Whatman DE81 ¢lter discs. After drying, the ¢lters were washed
three times for 5 min with 5% Na2HPO4, rinsed once with distilled
water and once with 70% ethanol. The radioactivity on the dried
¢lters was measured by liquid scintillation counting using UltimaGold
counting £uid (Packard).
2.6. Determination of intracellular ribonucleotide pools by HPLC
analysis
Exponentially growing K562, CEM and L1210 cells were harvested,
washed twice with cold RPMI 1640 medium without serum and lysed
with ice-cold 75% methanol. After incubation on ice for 10 min, the
cell extracts were centrifuged at 4‡C for 5 min at 15 000 rpm and the
supernatant was stored at 320‡C until HPLC analysis. The super-
natants were separated on an anion exchange Whatman Partisphere
SAX column (particle size: 10 Wm, column dimensions: 4.6U125
mm). The bu¡er gradient system was as follows: 5 min at 5 mM
(NH4)H2PO4 pH 5.0 (£ow rate: 2 ml/min), 15 min linear gradient
to 0.3 M (NH4)H2PO4 pH 5.0, 20 min at 0.3 M (NH4)H2PO4 pH
5.0, 5 min linear gradient to 5 mM (NH4)H2PO4 pH 5.0, 5 min
equilibration at the same bu¡er conditions. The eluting nucleotides
were detected by UV absorbance at 260 nm and quantitated by the
use of standard calibration curves. The retention times were 21, 23,
25 and 32 min for UTP, CTP, ATP and GTP, respectively.
2.7. Incorporation of [methyl-3H]thymidine and [6-3H]deoxyuridine
into DNA and thymine deoxyribonucleotide pools
Exponentially growing K562 and L1210 cells were pre-exposed dur-
ing 16 h to PMEA, ara-C or aphidicolin at the appropriate concen-
trations and were then loaded during 6 h with 1 WCi/ml [methyl-
3H]dThd (radiospeci¢city: 65 Ci/mmol) or 1 WCi/ml [6-3H]dUrd (ra-
diospeci¢city: 15.2 Ci/mmol) (Moravek Biochemicals). Thereafter,
methanol extracts were prepared and analyzed by HPLC as described
above. Determination of radiolabelled thymine deoxyribonucleotides
was accomplished by liquid scintillation counting of the correspond-
ing eluted fractions (i.e. 6^7 min, 13^14 min and 21^23 min for
dTMP, dTDP and dTTP, respectively), using OptiPhase ‘HiSafe’
3 counting £uid (Wallac, Turku, Finland). The radioactivity in the
thoroughly washed DNA pellets of the cells was also determined.
2.8. Determination of thymidine kinase (TK) activity in crude K562
cell extracts
Drug-exposed K562 cells were washed twice with PBS and once
with 100 mM Tris-HCl pH 7.8 containing 20 mM L-mercaptoethanol.
Then, the cells were lysed by sonication (two times 5 s) in Tris bu¡er.
After centrifugation (4‡C, 15 min, 15 000 rpm), the supernatants were
stored at 370‡C until further analysis. The reaction mixtures for the
TK assay contained 50 mM Tris-HCl pH 8.0, 2.5 mM MgCl2, 10 mM
1,4-dithiothreitol, 1 mg/ml bovine serum albumin, 2.5 mM ATP,
10 mM NaF and 1 WM [methyl-3H]thymidine (radiospeci¢city:
2.4 Ci/mmol) (Moravek Biochemicals). The reactions were started
by addition of 5 Wl cell extract. The total reaction volume was 50
Wl. At several time points (i.e. 0, 10, 20 or 30 min), 45 Wl of the
reaction mixtures was spotted onto Whatman DE81 ¢lter discs. After
drying, the ¢lters were washed three times 5 min with 1 mM ammo-
nium formate and thereafter once with distilled water and once with
70% ethanol. The radioactivity on the dried ¢lters was measured using
UltimaGold liquid scintillation counting £uid (Packard).
2.9. Immunoblotting
Protein extracts of drug-exposed K562 cells were prepared in cold
PBS containing 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS
and freshly added protease inhibitors. 50 Wg of protein was electro-
phoresed on 4^15% Tris-HCl Ready Gels (Bio-Rad, Hercules, CA,
USA) and subsequently blotted onto a Hybond-ECL nitrocellulose
membrane (Amersham-Pharmacia, Uppsala, Sweden). Aspeci¢c bind-
ing sites were blocked in 5% dried milk in PBS-T (i.e. PBS containing
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0.1% Tween-20). After rinsing, the membrane was incubated over-
night at 4‡C with monoclonal mouse anti-human cyclin-dependent
kinase (CDK)2 (clone D-12) (Calbiochem-Novabiochem, San Diego,
CA, USA), cyclin A (clone BF683) or cyclin E (clone HE12) (Phar-
Mingen-Becton Dickinson), diluted to 0.5^2.5 Wg/ml in PBS-T con-
taining 2% dried milk. After washing, the membrane was incubated
with peroxidase-linked sheep anti-mouse Ig antibody (Amersham) di-
luted in PBS-T containing 2% dried milk. After thorough washing of
the membrane, protein bands were visualized by enhanced chemilu-
minescence detection (Amersham).
3. Results
3.1. Accumulation of PMEA-exposed tumor cells in the
S phase of the cell cycle
Fig. 2 shows the cell cycle distribution of human erythro-
leukemia K562, human T-lymphoid CEM and murine leuke-
mia L1210 cell cultures, exposed to PMEA for 24 h. The
percentage of drug-treated K562 cells residing in the S phase
gradually increased with increasing PMEA concentrations (i.e.
45%, 49%, 58% and 65% at 0, 5, 50 and 500 WM PMEA,
respectively) while the percentage of K562 cells in the G1
phase reciprocally decreased (i.e. 44%, 37%, 27% and 21%,
respectively). The proportion of K562 cells in the G2/M phase
remained virtually constant (i.e. 11^15%) in the presence of
the di¡erent PMEA concentrations (Fig. 2A). A similar trend
was observed for PMEA-exposed CEM and L1210 cell cul-
tures (Fig. 2B,C).
3.2. E¡ect of PMEA on RNA and protein synthesis
The e¡ects of PMEA on RNA and protein synthesis were
investigated by measuring the incorporation of radiolabelled
uridine and leucine, respectively, in the acid insoluble fraction
of PMEA-exposed (1.6, 8, 40, 200 or 1000 WM for 24 h) versus
control K562, CEM and L1210 cells. No appreciable inhib-
itory activity of PMEA was noted under these experimental
conditions. The 50% inhibitory concentration of PMEA was
s 1 mM for both uridine and leucine incorporation in all
three tumor cell lines (data not shown). Thus, it was con-
cluded that, in contrast to DNA synthesis, RNA and protein
synthesis were not markedly inhibited in PMEA-treated K562,
CEM and L1210 cells.
3.3. Accumulation of intracellular dNTP and NTP pools in
PMEA-exposed tumor cells
K562, CEM and L1210 cells were exposed to PMEA at V2
and V10 times its IC50 in the di¡erent cell lines. After 24 h,
the intracellular dNTP pools were measured by an enzymatic
assay using the Klenow fragment of E. coli DNA polymerase
I and alternating copolymer templates. All four dNTPs mark-
edly accumulated intracellularly in the presence of PMEA.
The intracellular levels of dATP, dCTP, dGTP and dTTP
increased from 100% (control) to 224%, 261%, 288% and
330%, respectively, in K562 cells exposed to 50 WM PMEA
and to 293%, 299%, 354% and 446%, respectively, in the pres-
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Fig. 2. E¡ect of PMEA on the cell cycle distribution of K562 cell
cultures. K562 cells were exposed to PMEA at varying concentra-
tions for 24 h. Thereafter, the DNA content of drug-treated and un-
treated K562 cells was analyzed by propidium iodide staining and
£ow cytometry.
Fig. 1. Structural formula of PMEA.
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ence of 250 WM PMEA (Fig. 3, left panel). Likewise, the four
dNTPs accumulated to 1.5^4-fold their respective control val-
ues in CEM cells treated with 100 or 500 WM PMEA and to
1.5^3-fold their respective control values in L1210 cells treated
with 20 or 100 WM PMEA (data not shown).
We also examined the e¡ect of PMEA on the intracellular
ribonucleoside triphosphate levels. After 24 h exposure to 50
WM PMEA, K562 cells showed NTP pool size elevations from
100% (control) to 139%, 153%, 161% and 141% for ATP,
CTP, GTP and UTP, respectively. In K562 cells exposed to
250 WM PMEA, the ATP, CTP, GTP and UTP levels in-
creased to 167%, 175%, 172% and 166%, respectively (Fig.
3, right panel). A similar modest accumulation (1.4^2-fold)
of all four NTPs was also observed in PMEA-treated CEM
and L1210 cells (data not shown).
3.4. Incorporation of de novo TS-derived thymine
deoxyribonucleotides in PMEA-exposed K562 cells
K562 cells were pre-incubated with PMEA for 16 h and
subsequently exposed to [6-3H]deoxyuridine (dUrd) for anoth-
er 6 h in the continued presence of PMEA. The amounts of
dUrd-derived thymine deoxyribonucleotides that had been in-
corporated in the cellular DNA of K562 cells exposed to 50
and 200 WM PMEA were respectively 4- and 14-fold lower
than in untreated control cells (Table 1). In the presence of
PMEA, 2^4-fold accumulations of dUrd-derived dTMP,
dTDP and dTTP were noted (Table 1).
3.5. E¡ect of PMEA on the salvage of exogenous radiolabelled
thymidine
K562 and L1210 cell cultures were pre-incubated with
PMEA for 16 h and subsequently exposed to radiolabelled
thymidine for another 6 h in the continued presence of
PMEA. In contrast to the observations made with dUrd,
the incorporation of exogenous radiolabelled dThd into
DNA was unaltered in the presence of 50 WM PMEA (Table
2). At 200 WM, the amount of radiolabelled dThd that was
incorporated into DNA (i.e. 705 pmol/109 cells) was only 3-
fold lower than in untreated K562 cells (i.e. 2099 pmol/109
cells) (Table 2). Following PMEA treatment, dThd-derived
(i.e. TK-derived) thymine deoxyribonucleotides accumulated
to a much higher extent in the acid soluble pools of K562
cells (i.e. 25^32-fold for dTMP, 9^12-fold for dTDP and 23^
31-fold for dTTP) (Table 2) than did dUrd-derived thymine
deoxyribonucleotides (i.e. only 2^4-fold) (Table 1). Such pro-
nounced stimulation of dThd incorporation into the acid solu-
ble thymine deoxyribonucleotide pools (i.e. 14^43-fold for
each dTMP, dTDP and dTTP) was also observed in
PMEA-treated CEM and L1210 cells (data not shown).
These ¢ndings prompted us to examine the e¡ect of PMEA
on the global activity of the salvage enzyme TK in drug-
treated cell cultures. We found a gradual increase of TK ac-
tivity in K562 cell cultures exposed to increasing PMEA con-
centrations. The amount of radiolabelled thymidine that was
converted to thymine deoxyribonucleotides within 10 min by
crude K562 cell extracts was 0.16 nmol/106 cells for control
K562 cell cultures and 0.20, 0.31, 0.47 and 0.57 nmol/106 cells
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Table 2
Incorporation of thymidine-derived thymine deoxyribonucleotides in
K562 cells exposed to PMEA
PMEA (WM) pmol/109 cellsa
dTMP dTDP dTTP DNA
0 1.1 4.4 40 2099
50 27 40 935 2047
200 35 51 1244 705
aThe data were calculated from the radioactivity measured in the
DNA and in the thymine deoxyribonucleotide pools of drug-exposed
versus untreated K562 cells, loaded with [methyl-3H]thymidine. The
results represent the means for two independent experiments.
Table 1
Incorporation of deoxyuridine-derived thymine deoxyribonucleotides
in K562 cells exposed to PMEA
PMEA (WM) pmol/109 cellsa
dTMP dTDP dTTP DNA
0 10 14 346 7005
50 39 62 1452 1820
200 25 32 831 507
aThe data were calculated from the radioactivity measured in the
DNA and in the thymine deoxyribonucleotide pools of drug-exposed
versus untreated K562 cells, loaded with [6-3H]deoxyuridine. The re-
sults represent the means for two independent experiments.
Fig. 3. Intracellular accumulation of (deoxy)ribonucleotides in K562 cells exposed to PMEA. The 2P-deoxyribonucleoside 5P-triphosphates (left
panel) were quantitated by an enzymatic assay. The absolute amounts of dATP, dCTP, dGTP and dTTP in untreated control cells were 34, 32,
8 and 52 pmol/106 cells. The ribonucleoside 5P-triphosphates (right panel) were measured by HPLC analysis. The absolute amounts of ATP,
CTP, GTP and UTP in untreated control cells were 7620, 724, 1333 and 3842 pmol/106 cells. All data are expressed as percentages of the pool
sizes measured in untreated control cells and represent the means of two independent experiments.
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for K562 cell cultures incubated for 24 h with PMEA at 2, 10,
50 or 250 WM, respectively.
3.6. E¡ect of PMEA on cyclin E, cyclin A and CDK2
expression in K562 cells
Cyclins associate with and regulate the protein kinase ac-
tivity of CDKs during the cell cycle. Since the CDK2/cyclin E
and CDK2/cyclin A complexes are known to play crucial roles
in S phase initiation and S phase progression, respectively, we
decided to measure the protein levels of CDK2 and cyclins E
and A in untreated K562 cells versus K562 cells exposed to
100 WM PMEA for 24 h. Striking increases of the cyclin E and
cyclin A protein levels were noted in PMEA-exposed K562
cells, as compared to the control (Fig. 4). Also, the CDK2
protein level was slightly elevated in the presence of PMEA
(Fig. 4). The DNA synthesis inhibitors aphidicolin and ara-C
a¡orded similar cyclin and CDK2 accumulations (data not
shown).
4. Discussion
The antiretroviral properties and intracellular metabolism
of the acyclic nucleoside phosphonate analogue PMEA are
well documented [1^8]. In contrast, the antimetabolic e¡ects
elicited by the drug at the cellular level have remained largely
unknown. Therefore, we have now studied the impact of
PMEA on cell cycle distribution and (deoxy)ribonucleotide
metabolism in the human erythroleukemia K562, human T-
lymphoid CEM and murine leukemia L1210 tumor cell lines.
Because the K562 cell line has been extensively used in our
laboratory to investigate the di¡erentiation inducing proper-
ties of PMEA [9,10], the present report is focused on the
results obtained with the K562 cells. However, it should be
noted that the experiments with CEM and L1210 cells con-
sistently led to similar conclusions.
Flow cytometric analysis of the DNA content of K562,
CEM and L1210 cells in function of time revealed a marked
retardation of S phase progression in the presence of PMEA,
leading to the accumulation of S phase cells and a severe
perturbation of the normal cell cycle distribution pattern.
The observation that this phenomenon became increasingly
apparent at higher drug concentrations is in agreement with
the fact that the active drug metabolite PMEApp inhibits
cellular DNA polymerases in a competitive manner [3]. More-
over, we have previously shown that the cellular uptake of
PMEA by K562 cells and the subsequent conversion to its
metabolically active form PMEApp occurs proportionally
with the extracellular PMEA concentration up to 2 mM
[16]. Thus, the detrimental e¡ect of PMEA on the tumor cells
should increase with increasing drug concentrations.
The marked increases (2^4-fold) in the dNTP pool sizes
noted in PMEA-treated K562 cells are in agreement with
the observations of Nicander and Reichard that the de novo
synthesis of DNA precursors continues when DNA synthesis
is blocked by aphidicolin [17]. Consequently, the dNTP sub-
strates for the DNA polymerisation reaction accumulate in
the presence of aphidicolin and PMEA due to their decreased
consumption. Since we found that PMEA does not act as an
inhibitor of RNA synthesis, the moderate accumulation of
NTPs in PMEA-exposed cells can be attributed to feedback
inhibition of ribonucleotide reductase by excess of dATP [18].
DNA synthesis in PMEA-exposed K562 cells was estimated
by the use of radiolabelled nucleoside precursors. Consistent
with the inhibition of DNA polymerases K, N and O by
PMEApp (IC50 of PMEApp against puri¢ed mammalian
DNA polymerase K : 1.8 WM [3]), markedly less dUrd-derived
dTTP, synthesized via the de novo thymidylate synthase path-
way, was consumed for DNA polymerisation in the presence
of PMEA. The 2^4-fold increase of dUrd incorporation in the
dTTP pool of PMEA-exposed, compared to control, K562
cells is consistent with the overall 3^4-fold expansion of the
total (non-labelled) dTTP pool, as measured by the enzymatic
dNTP assay after 24 h of PMEA exposure.
A di¡erent picture was obtained when radiolabelled dThd
was used to measure thymine deoxyribonucleotide metabolism
and DNA synthesis. The incorporation of exogenous thymi-
dine into DNA was only93-fold lower in PMEA-exposed
than in control K562 cells. Thus, the use of dThd as a radio-
labelled precursor instead of dUrd resulted in an overestima-
tion of DNA synthesis by about 4-fold. Also, the dramatic
accumulation (i.e. 16^40-fold) of dThd-derived dTTP in the
acid soluble pool of PMEA-treated K562, CEM and L1210
cells could not be explained by the increased dTTP pool size
alone. Apparently, the salvage pathway of dTTP supply was
highly active in PMEA-exposed cells. This was quite unex-
pected, since dTTP has been shown to inhibit puri¢ed TK
at an IC50 value of 10 WM in a cell free assay (our unpublished
data). In PMEA-exposed K562 cells, dTTP accumulated to
intracellular concentrations up to approximately 90 WM, and
thus, TK activity would be predicted to be substantially de-
creased under these conditions. We have ascertained that
PMEA does not directly stimulate the enzymatic activity of
puri¢ed cytosolic TK (our unpublished data).
Our ¢ndings that a comparably high accumulation of sal-
vage-derived dTTP also occurred upon exposure of K562 cells
to aphidicolin and ara-C (data not shown) indicate that this
phenomenon must be related to the inhibition of DNA syn-
thesis, which is common to all three compounds. Since TK is
a cell cycle-dependent (S phase-speci¢c) enzyme [19,20], its
activity might be arti¢cially increased in cell cultures exposed
to agents (e.g. PMEA) that block cell cycle progression
through the S phase. We could indeed demonstrate a 3.5-
fold elevated TK activity in crude cell extracts from PMEA-
exposed (S phase-enriched) compared to untreated K562 cell
cultures. Thus, the dTTP-mediated feedback inhibition of TK
may be counterbalanced by the higher expression level of TK,
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Fig. 4. Accumulation of CDK2, cyclin E and cyclin A in K562 cells
exposed to PMEA for 24 h. The protein bands were visualized by
immunological staining of Western blots and enhanced chemilumi-
nescence detection. CDK2, cyclin E and cyclin A migrated at molec-
ular weigths of 33, 50 and 60 kDa, respectively. The blots from one
representative experiment are shown.
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caused by the drug-induced accumulation of S phase cells.
This may explain why the total amount of exogenous radio-
labelled dThd that was incorporated in cellular constituents
(i.e. soluble dTMP, dTDP and dTTP pools and DNA) did not
decrease in the presence of PMEA.
It is worth mentioning that PMEApp is a poor inhibitor of
the human DNA polymerase L, which is responsible for DNA
excision repair [21]. Moreover, it has been suggested that the
salvage pathways of deoxyribonucleotide synthesis play an
important role in providing the substrates for DNA repair
and the mitochondrial DNA replication [22]. Hence, it is pos-
sible that a potential stimulation of DNA repair in PMEA-
treated cells accounts, at least in part, for the observed salvage
activity and incorporation of radiolabelled dThd into DNA.
We have also found a pronounced accumulation of cyclin E
and modest increases in cyclin A and CDK2 protein levels in
K562 cells exposed to each of the three DNA synthesis inhib-
itors PMEA, aphidicolin and ara-C. Interestingly, CDK2 and
cyclins A and E are part of nuclear protein complexes with the
transcription factor E2F, which bind to the promoter region
of the TK gene and act as positive regulators of the S phase-
speci¢c TK gene transcription [23]. Thus, the increased abun-
dance of CDK2 and cyclins A and E may also contribute to
the observed stimulation of TK activity in PMEA-exposed
K562 cells.
In conclusion, (the active metabolite of) PMEA has pro-
found e¡ects on (deoxy)ribonucleotide metabolism and pool
levels, resulting from the inhibition of the DNA polymerisa-
tion process and the accumulation of drug-exposed cells in the
S phase of the cell cycle. Most particularly, increased dNTP
pool sizes and markedly elevated activity of the S phase-spe-
ci¢c salvage enzyme TK were observed following PMEA
treatment of K562 cell cultures. Our data also indicate that
caution should be exercised when using thymidine incorpora-
tion into DNA as a parameter to evaluate the anti-prolifer-
ative e¡ects of S phase-speci¢c agents like PMEA.
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